136 results on '"Eschbach C"'
Search Results
2. SOP – Inappetenz und Kachexie
3. SOP – Inappetenz und Kachexie
4. Behandlungsbelastung am Lebensende bei Lungenkrebspatienten: Einfluss von unterschiedlichen tumorspezifischen Maßnahmen und unterschiedlichen Gruppendefinitionen auf die Beurteilung der Qualität
5. SOP – inappetence and cachexia
6. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer
7. Frühe palliative Intervention: Vierte Modalität beim metastasierten Lungenkarzinom
8. Tumor epidermal growth factor receptor (EGFR) expression as a predictive biomarker of survival in FLEX study patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy plus cetuximab as firstline therapy: V446
9. A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer (NSCLC): V958
10. Baseline population description of the German patient population in the EPICLIN-Lung epidemiological study in Non-Small Cell Lung Cancer (NSCLC) across Europe: PO240
11. Cetuximab treatment in combination with gemcitabine/docetaxel or carboplatin/gemcitabine for chemonaïve patients with advanced non-small cell lung cancer (NSCLC): Report on toxicity data from the ongoing Phase II/III GemTax IV study: PP403
12. THE ACCURACY OF VO2MAX ESTIMATION FROM THREE COMMONLY USED SUBMAXIMAL EXERCISE TESTS
13. SOP – Inappetenz und Kachexie
14. A longitudinal communication approach in advanced lung cancer: A qualitative study of patients', relatives' and staff's perspectives
15. A longitudinal communication approach in advanced lung cancer: A qualitative study of patients’, relatives’ and staff's perspectives
16. spiel ohne grenzen/pou2 Is Required for Early Steps in the Establishment of the Zebrafish Mid-/Hindbrain Boundary
17. Baseline population description of the German patient population in the EPICLIN-Lung epidemiological study in Non-Small Cell Lung Cancer (NSCLC) across Europe
18. Differential conditioning and long-term olfactory memory in individual Camponotus fellah ants
19. Frühe palliative Intervention
20. De strategische rol van het middenkader. Een verkennende studie in de energiesector
21. 9096 POSTER EGFR-targeting Chimeric Monoclonal lgG-1 Antibody Cetuximab in a Phase ll/lll Study Added Either to Gemcitabine Followed by Docetaxel or Carboplatin Plus Gemcitabine for Chemonaive Patients With Advanced Non-small Cell Lung Cancer (NSCLC) – Results of the Phase II Study Part
22. Influence of expression of estrogen (ERS-1) and progesterone (PGR) receptors on metastatic spread and outcome in non-small cell lung cancer (NSCLC).
23. Klinisches Management von Patienten mit nicht-kleinzelligem Lungenkrebs (NSCLC) im Therapiealltag in Deutschland: Daten der europäischen EPICLIN-Lung Studie
24. Ranpirnase + Doxorubicin versus Doxorubicin bei Patienten mit nicht operablem Mesotheliom – eine randomisierte Phase III Studie
25. 9077 Phase 2 study of pemetrexed and cisplatin plus either enzastaurin or placebo in chemonaive patients with advanced NSCLC
26. 9144 Cetuximab in combination with gemcitabine/docetaxel or carboplatin/gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: toxicity data from an ongoing Phase II/III trial (GemTax IV)
27. 9152 A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small cell lung cancer
28. Cetuximab combined with either gemcitabine (G) followed by docetaxel (D) or carboplatin/gemcitabine (CP/G) in chemotherapy-naive patients (pts) with advanced non-small cell lung cancer (NSCLC): Safety profile from the ongoing phase II/III GemTax IV trial
29. First-line treatment patterns in advanced NSCLC in western Europe (EU), the United States, and Japan including a comparative analysis of younger versus elderly patients
30. Randomized, multicenter phase III study of ranpirnase plus doxorubicin (DOX) versus DOX in patients with unresectable malignant mesothelioma (MM)
31. Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): Data from the FLEX study
32. Palliativmedizin in der Pneumologie
33. GEMTAX IV Studie: Studienstand und Toxizitätsdaten
34. Eine neue Kombination in der Erstlinientherapie des Nicht-Kleinzelligen Bronchialcarcinoms: Bevacizumab, Pemetrexed und Cisplatin – Ein Fallbericht
35. FLEX: Cetuximab in Kombination mit Platin-basierter Chemotherapie (CT) verlängert das Überleben in der Erstlinientherapie von Patienten mit fortgeschrittenem nicht-kleinzelligen Bronchialkarzinom (non-small cell lung cancer, NSCLC) im Vergleich zur alleinigen CT
36. A population pharmacokinetic analysis for BIBF 1120, an angiokinase inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC)
37. Topotecan/cisplatin (TP) compared to cisplatin/etoposide (PE) for patients with extensive disease-small cell lung cancer (ED- SCLC): Final results of a randomised phase III trial
38. Feasibility of cetuximab in combination with gemcitabine or docetaxel or carboplatin/gemcitabine for chemonaïve patients with advanced non-small cell lung cancer (NSCLC): Observations from an ongoing randomized phase II/III trial (GemTax IV)
39. ZK-EPO (Sagopilone) als Zweitlinientherapie bei Patienten mit Nicht-Kleinzelligem Bronchialkarzinom (NSCLC) im Stadium IIIB oder IV
40. 6568 POSTER Phase II trial of the novel epothilone ZK-EPO as second-line therapy in patients with stage IIIB or stage IV non-small-cell lung cancer
41. A double blind phase II study of BIBF 1,120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
42. A pilot study on the effect of oral contraceptives on electromyography and mechanomyography during isometric muscle actions
43. Comparison of the incentives used to stimulate energy production in Japan, France, West Germany, and the United States
44. Obstacles and opportunities in the commercialization of the solid-state-electronic fluorescent-lighting ballast
45. Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer: final results of a randomized phase III trial.
46. Tasisulam sodium (LY573636 sodium) as third-line treatment in patients with unresectable, metastatic non-small-cell lung cancer: a phase-II study.
47. Organocobalt Cluster Complexes. XXIII. Clemmenszn and Borane Reductions of Acyl-and Vinylic Methylidynetri-Cobalt Nonacarbonyl Complexes.
48. spiel ohne grenzen/pou2 is required during establishment of the zebrafish midbrain-hindbrain boundary organizer.
49. Zebrafish Dkk1, induced by the pre-MBT Wnt signaling, is secreted from the prechordal plate and patterns the anterior neural plate
50. The similarity between odors and their binary mixtures in Drosophila
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.